Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy and Radiation Therapy in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed or Refractory Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic diagnosis of Classical Hodgkin's Lymphoma. Lymphocyte predominant histology will be excluded.~* Primary refractory or relapsed disease proven by biopsy or fine needle aspiration (cytology) of an involved site~* Failure of doxorubicin or nitrogen mustard containing front-line therapy~* 18F-fluorodeoxyglucose-PET scan demonstrating PET avid disease~* Cardiac ejection fraction of greater than 45%, measured since last chemotherapy.~* Adjusted diffusing capacity of greater than 50% on pulmonary function testing, measured since last chemotherapy~* Serum creatinine \< than or = to 1.5 mg/dl; if creatinine \>1.5 mg/dl then the measured 12- or 24-hour creatinine clearance must be \>60 ml/minute.~* ANC\>1000/μl and Platelets\>50,000/μl~* Total bilirubin \< than or = to 2.0 mg/dl in the absence of a history of Gilbert's disease.~* Females of childbearing age must be on an acceptable form of birth control.~* Age between 18 and 72~* HIV I and II negative.~* Patients or their guardians must be capable of providing informed consent.~Exclusion Criteria:~Histology for Lymphocyte predominant subtype Hodgkin's Lymphoma~* Prior treatment with carboplatin, cisplatin, ifosfamide, gemcitabine, or vinorelbine~* Hepatitis B surface antigen positive.~* Known pregnancy or breast-feeding.~* Medical illness unrelated to Hodgkin's Lymphoma, which, in the opinion of the attending physician and/or principal investigator, will preclude administering chemotherapy safely.~* History of any malignancy for which the disease-free interval is \<5 years, excluding curatively treated cutaneous basal cell or squamous cell carcinoma and carcinoma in-situ of the cervix

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 72 Years
- Healthy Volunteers: f

Study Arms:
- Cytoreductive chemotherapy group 1 (Type: EXPERIMENTAL): Patients receive ICE comprising ifosfamide IV and carboplatin IV once on day 2 and etoposide IV over 1 hour once daily on days 1-3. Patients then receive ifosfamide IV twice on day 15, carboplatin IV once on day 17 and etoposide IV over 1 hour twice daily on days 15-17.
- Cytoreductive chemotherapy group 2 (Type: EXPERIMENTAL): Patients receive ifosfamide IV twice on days 1 and 17, carboplatin IV once on days 3 and 19, and etoposide IV over 1 hour twice daily on days 1-3 and 17-19.

Based on this trial design, predict the completion outcome and termination type (if applicable).